Inactive Instrument

Radius Health, Inc.

RDUS

US7504692077

Biotechnology & Medical Research

Radius Health, Inc. Reiterates Revenue Guidance for the Full Year of Fiscal 2021

May 07, 2021 at 11:30 am

Radius Health, Inc. reiterated revenue guidance for the full year of fiscal 2021. For the year, the company expects revenue of $250 million.

Latest news about Radius Health, Inc.

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States	19/09/23	CI
Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development	27/07/23	CI
Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel	06/04/23	CI
Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil	20/03/23	CI
Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC	30/12/22	CI
Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture	20/12/22	CI
Ambrx Biopharma Names Kate Hermans Interim CEO	16/08/22	MT
Radius Health, Inc. Announces Board Changes	15/08/22	CI
Radius Health, Inc. Enters into Credit Agreement	15/08/22	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index	15/08/22	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index	15/08/22	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Global BMI Index	15/08/22	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Biotechnology Select Industry Index	15/08/22	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Biotechnology Index	10/08/22	CI
Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. from Repertoire Partners LP, Velan Capital Investment Management LP and others.	09/08/22	CI
Radius Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Radius Health, Inc. and Teijin Pharma Limited Enter into an Amendment to License and Development Agreement	02/08/22	CI
Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health	11/07/22	CI
Radius Health Inc Issues an Investor Presentation to Shareholders	08/07/22	CI
Radius Health Solicits Proxies from Shareholders	07/07/22	CI
Radius Health Says First Patient Randomized in Trial of Prader-Willi Syndrome Symptoms	07/07/22	MT
Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome	07/07/22	CI
Radius Health, Inc Provides Information to the Shareholders	27/06/22	CI
Velan Capital Investment Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital	24/06/22	CI
SVB Securities Adjusts Radius Health's Price Target to $10 from $7, Keeps Market Perform Rating	24/06/22	MT

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs